The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)

被引:105
作者
Costelloe, Lisa
O'Rourke, Killian
Kearney, Hugh
McGuigan, Christopher
Gribbin, Lisa
Duggan, Marguerite
Daly, Leslie
Tubridy, Niall
Hutchinson, Michael [1 ]
机构
[1] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland
[2] Univ Coll Dublin, Sch Publ Hlth Med & Populat Sci, Dublin 2, Ireland
关键词
D O I
10.1136/jnnp.2006.105759
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim: The aims of this study were to determine the reliability, responsiveness and minimally important change score of the Multiple Sclerosis Impact Scale (MSIS)-29 physical using the Expanded Disability Status Scale (EDSS) as an anchor measure. Methods: 214 patients with multiple sclerosis ( MS) ( EDSS 0-8.5) had concurrent MSIS-29 and EDSS assessments at baseline and at up to 4 years of follow-up. Results: 116 patients had unchanged EDSS scores. Stability of the MSIS-29 physical ( mean change 0.1 points) was better in the 85 patients with EDSS 0-5.0 than in the 31 patients with EDSS 5.5-8.5 in whom the MSIS-29 physical score fell by 8 points, a response shift phenomenon. A floor effect for the MSIS-29 was observed in 5% of stable patients at both time points. 98 patients experienced EDSS change with moderately strong statistically significant correlations between change scores in the EDSS and the MSIS-29 physical (r = 0.523, p < 0.0001). Effect sizes for MSIS-29 physical change were moderate to large. Using receiver operating characteristic curves, the MSIS-29 change score which produced a combination of optimal sensitivity and specificity was chosen for both EDSS ranges. For EDSS range 5.5-8, a change score of 8 had a sensitivity of 87% and specificity of 67%. For EDSS 0-5.0, a change score of 7 had a sensitivity of 78% and a specificity of 51%. Conclusions: The MSIS-29 physical performs well over time, and is suitable for use in trials; a minimal change score of 8 points in the MSIS-29 is clinically significant.
引用
收藏
页码:841 / 844
页数:4
相关论文
共 16 条
[1]   A POWER PRIMER [J].
COHEN, J .
PSYCHOLOGICAL BULLETIN, 1992, 112 (01) :155-159
[2]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[3]   The Multiple Sclerosis Impact Scale (MSIS-29) - A new patient-based outcome measure [J].
Hobart, J ;
Lamping, D ;
Fitzpatrick, R ;
Riazi, A ;
Thompson, A .
BRAIN, 2001, 124 :962-973
[4]   How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales [J].
Hobart, JC ;
Riazi, A ;
Lamping, DL ;
Fitzpatrick, R ;
Thompson, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (11) :1539-1543
[5]   Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability [J].
Hoogervorst, ELJ ;
Zwemmer, JNP ;
Jelles, B ;
Polman, CH ;
Uitdehaag, BMJ .
MULTIPLE SCLEROSIS, 2004, 10 (05) :569-574
[6]   The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite [J].
Hoogervorst, ELJ ;
Kalkers, NF ;
Cutter, GR ;
Uitdehaag, BMJ ;
Polman, CH .
MULTIPLE SCLEROSIS, 2004, 10 (01) :55-60
[7]   One year changes in disability in multiple sclerosis: neurological examination compared with patient self report [J].
Hoogervorst, ELJ ;
Eikelenboom, MJ ;
Uitdehaag, BMJ ;
Polman, CH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (04) :439-442
[8]   A study validating changes in the Multiple Sclerosis Functional Composite [J].
Hoogervorst, ELJ ;
Kalkers, NF ;
Uitdehaag, BMJ ;
Polman, CH .
ARCHIVES OF NEUROLOGY, 2002, 59 (01) :113-116
[9]   EFFECT SIZES FOR INTERPRETING CHANGES IN HEALTH-STATUS [J].
KAZIS, LE ;
ANDERSON, JJ ;
MEENAN, RF .
MEDICAL CARE, 1989, 27 (03) :S178-S189
[10]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444